Loading…
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group
Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we ana...
Saved in:
Published in: | Annals of surgical oncology 2000-09, Vol.7 (8), p.617-623 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 623 |
container_issue | 8 |
container_start_page | 617 |
container_title | Annals of surgical oncology |
container_volume | 7 |
creator | Nielsen, H J Christensen, I J Sørensen, S Moesgaard, F Brünner, N |
description | Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we analyzed the association between plasma PAI-1 and serum CRP in patients scheduled for elective resection of colorectal cancer. In addition, the prognostic value of PAI-1 and CRP was studied in this patient cohort.
PAI-1 and CRP were analyzed in citrated plasma and serum, respectively, obtained preoperatively from 594 patients. Patients who required preoperative blood transfusion received SAGM blood, in which soluble PAI-1 is not present. None of the patients received pre- or postoperative adjuvant chemotherapy, and all were followed in the outpatient clinic for at least 5 years or until death. The association of PAI-1 and CRP, respectively, with survival was tested using the median value of PAI-1 and the upper normal limit for CRP. Analyses were performed by inclusion of all patients, and in the subgroup of patients, who underwent curative resection.
The median follow-up period was 6.8 (5.4-7.9) years. The median value of plasma PAI-1 was 35.8 ng/ml, and values greater than 94 nmol/L identified patients with increased CRP levels. Comparison of the molecules showed that PAI-1 was weakly correlated with CRP (r = .26; P |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72290761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72290761</sourcerecordid><originalsourceid>FETCH-LOGICAL-p541-aa2eaae11ae8afa662bfa99b94aebc6dfc1c2546452006cc2e4f09f1746f828e3</originalsourceid><addsrcrecordid>eNpFkEFOwzAQRbMA0VK4AvKKXZDtxk6yrCIoSBUg6IJdNHEm1MiJg-0U9UxcktAWsfojvTdfmjmJpozKLM65FJPo3PsPSlk6p-IsmjBGqRCSTaPvZ4e2RwdBb5H0BnwLh9CdfceOgBoJBOuI7ja60r9T2PUYMwJdTTy6oSVF7HAvjhXOBtQdMbhF48cl0o_d2AVPvnTYEGWNdagCGKKgU-huyHqD5GXx-EYFKf5psafkNQz1jiydHfqL6LQB4_HymLNofXe7Lu7j1dPyoVis4l4kLAbgCICMAWbQgJS8aiDPqzwBrJSsG8UUF4lMBKdUKsUxaWjesDSRTcYznM-i60PteMrngD6UrfYKjYEO7eDLlPOcppKN4tVRHKoW67J3ugW3K_--O_8Bhqt5cw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72290761</pqid></control><display><type>article</type><title>Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group</title><source>Springer Nature</source><creator>Nielsen, H J ; Christensen, I J ; Sørensen, S ; Moesgaard, F ; Brünner, N</creator><creatorcontrib>Nielsen, H J ; Christensen, I J ; Sørensen, S ; Moesgaard, F ; Brünner, N</creatorcontrib><description>Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we analyzed the association between plasma PAI-1 and serum CRP in patients scheduled for elective resection of colorectal cancer. In addition, the prognostic value of PAI-1 and CRP was studied in this patient cohort.
PAI-1 and CRP were analyzed in citrated plasma and serum, respectively, obtained preoperatively from 594 patients. Patients who required preoperative blood transfusion received SAGM blood, in which soluble PAI-1 is not present. None of the patients received pre- or postoperative adjuvant chemotherapy, and all were followed in the outpatient clinic for at least 5 years or until death. The association of PAI-1 and CRP, respectively, with survival was tested using the median value of PAI-1 and the upper normal limit for CRP. Analyses were performed by inclusion of all patients, and in the subgroup of patients, who underwent curative resection.
The median follow-up period was 6.8 (5.4-7.9) years. The median value of plasma PAI-1 was 35.8 ng/ml, and values greater than 94 nmol/L identified patients with increased CRP levels. Comparison of the molecules showed that PAI-1 was weakly correlated with CRP (r = .26; P <.0001). Both molecules showed a Dukes independent distribution. In univariate survival analyses high levels of PAI-1 were found associated with poor prognosis and low levels with good prognosis (P = .02, HR: 1.3). Similarly, high levels of CRP were found associated with poor prognosis and low levels with good prognosis (P <.0001, HR: 1.9). In a multivariate statistical analysis including Dukes classification, gender, age, tumor location, perioperative blood transfusion, PAI-1 and CRP, plasma PAI-1 was a dependent prognostic variable, while serum CRP (P <.0001; HR: 1.4; 95% CI: 1.3-1.5) was found to be a Dukes independent prognostic variable. Similar analyses, excluding patients with Dukes' D disease showed serum CRP to be an independent prognostic variable (P <.0001; HR: 1.3: 95% CI: 1.2-1.5).
This study did not show a strong correlation between plasma PAI-1 and serum CRP in patients with colorectal cancer. Serum CRP was found to be a Dukes independent prognostic variable in this patient cohort, and was found to identify a subgroup of curatively resected patients at risk for short survival.</description><identifier>ISSN: 1068-9265</identifier><identifier>PMID: 11005561</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Aged, 80 and over ; C-Reactive Protein - metabolism ; Colorectal Neoplasms - blood ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - surgery ; Data Interpretation, Statistical ; Double-Blind Method ; Follow-Up Studies ; Histamine H2 Antagonists - therapeutic use ; Humans ; Middle Aged ; Plasminogen Activator Inhibitor 1 - blood ; Preoperative Care ; Prognosis ; Ranitidine - therapeutic use ; Survival Analysis</subject><ispartof>Annals of surgical oncology, 2000-09, Vol.7 (8), p.617-623</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11005561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nielsen, H J</creatorcontrib><creatorcontrib>Christensen, I J</creatorcontrib><creatorcontrib>Sørensen, S</creatorcontrib><creatorcontrib>Moesgaard, F</creatorcontrib><creatorcontrib>Brünner, N</creatorcontrib><title>Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we analyzed the association between plasma PAI-1 and serum CRP in patients scheduled for elective resection of colorectal cancer. In addition, the prognostic value of PAI-1 and CRP was studied in this patient cohort.
PAI-1 and CRP were analyzed in citrated plasma and serum, respectively, obtained preoperatively from 594 patients. Patients who required preoperative blood transfusion received SAGM blood, in which soluble PAI-1 is not present. None of the patients received pre- or postoperative adjuvant chemotherapy, and all were followed in the outpatient clinic for at least 5 years or until death. The association of PAI-1 and CRP, respectively, with survival was tested using the median value of PAI-1 and the upper normal limit for CRP. Analyses were performed by inclusion of all patients, and in the subgroup of patients, who underwent curative resection.
The median follow-up period was 6.8 (5.4-7.9) years. The median value of plasma PAI-1 was 35.8 ng/ml, and values greater than 94 nmol/L identified patients with increased CRP levels. Comparison of the molecules showed that PAI-1 was weakly correlated with CRP (r = .26; P <.0001). Both molecules showed a Dukes independent distribution. In univariate survival analyses high levels of PAI-1 were found associated with poor prognosis and low levels with good prognosis (P = .02, HR: 1.3). Similarly, high levels of CRP were found associated with poor prognosis and low levels with good prognosis (P <.0001, HR: 1.9). In a multivariate statistical analysis including Dukes classification, gender, age, tumor location, perioperative blood transfusion, PAI-1 and CRP, plasma PAI-1 was a dependent prognostic variable, while serum CRP (P <.0001; HR: 1.4; 95% CI: 1.3-1.5) was found to be a Dukes independent prognostic variable. Similar analyses, excluding patients with Dukes' D disease showed serum CRP to be an independent prognostic variable (P <.0001; HR: 1.3: 95% CI: 1.2-1.5).
This study did not show a strong correlation between plasma PAI-1 and serum CRP in patients with colorectal cancer. Serum CRP was found to be a Dukes independent prognostic variable in this patient cohort, and was found to identify a subgroup of curatively resected patients at risk for short survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>C-Reactive Protein - metabolism</subject><subject>Colorectal Neoplasms - blood</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Data Interpretation, Statistical</subject><subject>Double-Blind Method</subject><subject>Follow-Up Studies</subject><subject>Histamine H2 Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Preoperative Care</subject><subject>Prognosis</subject><subject>Ranitidine - therapeutic use</subject><subject>Survival Analysis</subject><issn>1068-9265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpFkEFOwzAQRbMA0VK4AvKKXZDtxk6yrCIoSBUg6IJdNHEm1MiJg-0U9UxcktAWsfojvTdfmjmJpozKLM65FJPo3PsPSlk6p-IsmjBGqRCSTaPvZ4e2RwdBb5H0BnwLh9CdfceOgBoJBOuI7ja60r9T2PUYMwJdTTy6oSVF7HAvjhXOBtQdMbhF48cl0o_d2AVPvnTYEGWNdagCGKKgU-huyHqD5GXx-EYFKf5psafkNQz1jiydHfqL6LQB4_HymLNofXe7Lu7j1dPyoVis4l4kLAbgCICMAWbQgJS8aiDPqzwBrJSsG8UUF4lMBKdUKsUxaWjesDSRTcYznM-i60PteMrngD6UrfYKjYEO7eDLlPOcppKN4tVRHKoW67J3ugW3K_--O_8Bhqt5cw</recordid><startdate>200009</startdate><enddate>200009</enddate><creator>Nielsen, H J</creator><creator>Christensen, I J</creator><creator>Sørensen, S</creator><creator>Moesgaard, F</creator><creator>Brünner, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200009</creationdate><title>Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group</title><author>Nielsen, H J ; Christensen, I J ; Sørensen, S ; Moesgaard, F ; Brünner, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p541-aa2eaae11ae8afa662bfa99b94aebc6dfc1c2546452006cc2e4f09f1746f828e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>C-Reactive Protein - metabolism</topic><topic>Colorectal Neoplasms - blood</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Data Interpretation, Statistical</topic><topic>Double-Blind Method</topic><topic>Follow-Up Studies</topic><topic>Histamine H2 Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Preoperative Care</topic><topic>Prognosis</topic><topic>Ranitidine - therapeutic use</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nielsen, H J</creatorcontrib><creatorcontrib>Christensen, I J</creatorcontrib><creatorcontrib>Sørensen, S</creatorcontrib><creatorcontrib>Moesgaard, F</creatorcontrib><creatorcontrib>Brünner, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nielsen, H J</au><au>Christensen, I J</au><au>Sørensen, S</au><au>Moesgaard, F</au><au>Brünner, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2000-09</date><risdate>2000</risdate><volume>7</volume><issue>8</issue><spage>617</spage><epage>623</epage><pages>617-623</pages><issn>1068-9265</issn><abstract>Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we analyzed the association between plasma PAI-1 and serum CRP in patients scheduled for elective resection of colorectal cancer. In addition, the prognostic value of PAI-1 and CRP was studied in this patient cohort.
PAI-1 and CRP were analyzed in citrated plasma and serum, respectively, obtained preoperatively from 594 patients. Patients who required preoperative blood transfusion received SAGM blood, in which soluble PAI-1 is not present. None of the patients received pre- or postoperative adjuvant chemotherapy, and all were followed in the outpatient clinic for at least 5 years or until death. The association of PAI-1 and CRP, respectively, with survival was tested using the median value of PAI-1 and the upper normal limit for CRP. Analyses were performed by inclusion of all patients, and in the subgroup of patients, who underwent curative resection.
The median follow-up period was 6.8 (5.4-7.9) years. The median value of plasma PAI-1 was 35.8 ng/ml, and values greater than 94 nmol/L identified patients with increased CRP levels. Comparison of the molecules showed that PAI-1 was weakly correlated with CRP (r = .26; P <.0001). Both molecules showed a Dukes independent distribution. In univariate survival analyses high levels of PAI-1 were found associated with poor prognosis and low levels with good prognosis (P = .02, HR: 1.3). Similarly, high levels of CRP were found associated with poor prognosis and low levels with good prognosis (P <.0001, HR: 1.9). In a multivariate statistical analysis including Dukes classification, gender, age, tumor location, perioperative blood transfusion, PAI-1 and CRP, plasma PAI-1 was a dependent prognostic variable, while serum CRP (P <.0001; HR: 1.4; 95% CI: 1.3-1.5) was found to be a Dukes independent prognostic variable. Similar analyses, excluding patients with Dukes' D disease showed serum CRP to be an independent prognostic variable (P <.0001; HR: 1.3: 95% CI: 1.2-1.5).
This study did not show a strong correlation between plasma PAI-1 and serum CRP in patients with colorectal cancer. Serum CRP was found to be a Dukes independent prognostic variable in this patient cohort, and was found to identify a subgroup of curatively resected patients at risk for short survival.</abstract><cop>United States</cop><pmid>11005561</pmid><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1068-9265 |
ispartof | Annals of surgical oncology, 2000-09, Vol.7 (8), p.617-623 |
issn | 1068-9265 |
language | eng |
recordid | cdi_proquest_miscellaneous_72290761 |
source | Springer Nature |
subjects | Adult Aged Aged, 80 and over C-Reactive Protein - metabolism Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - surgery Data Interpretation, Statistical Double-Blind Method Follow-Up Studies Histamine H2 Antagonists - therapeutic use Humans Middle Aged Plasminogen Activator Inhibitor 1 - blood Preoperative Care Prognosis Ranitidine - therapeutic use Survival Analysis |
title | Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20plasma%20plasminogen%20activator%20inhibitor%20type-1%20and%20serum%20C-reactive%20protein%20levels%20in%20patients%20with%20colorectal%20cancer.%20The%20RANX05%20Colorectal%20Cancer%20Study%20Group&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Nielsen,%20H%20J&rft.date=2000-09&rft.volume=7&rft.issue=8&rft.spage=617&rft.epage=623&rft.pages=617-623&rft.issn=1068-9265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72290761%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p541-aa2eaae11ae8afa662bfa99b94aebc6dfc1c2546452006cc2e4f09f1746f828e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72290761&rft_id=info:pmid/11005561&rfr_iscdi=true |